{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:18Z","timestamp":1790286918883,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10549-021-06169-9","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T08:02:52Z","timestamp":1615190572000},"page":"535-545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience"],"prefix":"10.1007","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-785X","authenticated-orcid":false,"given":"Sumir","family":"Chawla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Fearfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Parton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"6169_CR1","unstructured":"Cancer Research UK, https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive, Accessed [September 2019]"},{"issue":"1","key":"6169_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335","journal-title":"Lancet Oncol"},{"issue":"20","key":"6169_CR3","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"20","key":"6169_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"issue":"3","key":"6169_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H et al (2015) Palbociclib in hormone-receptor\u2013positive advanced breast cancer. N Engl J Med 373(3):209\u2013219","journal-title":"N Engl J Med"},{"key":"6169_CR6","unstructured":"CTCAE criteria: National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html [Accessed January 2020]"},{"issue":"15","key":"6169_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2019.37.15_suppl.1051","volume":"37","author":"J Pascual","year":"2019","unstructured":"Pascual J, MacPherson IR, Armstrong AC, Ward SE, Parmar M, Turner AJ et al (2019) PIPA: A phase Ib study of \u03b2-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. JCO. 37(15):1051\u20131051","journal-title":"JCO."},{"issue":"3","key":"6169_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol 19(3):345\u2013361","journal-title":"Am J Clin Dermatol"},{"key":"6169_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","volume":"2","author":"W Damsky","year":"2016","unstructured":"Damsky W, Kole L, Tomayko MM (2016) Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2:442\u2013444","journal-title":"JAAD Case Rep"},{"issue":"9","key":"6169_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","volume":"28","author":"PG Stavropoulos","year":"2014","unstructured":"Stavropoulos PG, Soura E, Antoniou C (2014) Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 28(9):1133\u20131140","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"6169_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s11606-016-3679-1","volume":"31","author":"SM Kanahara","year":"2016","unstructured":"Kanahara SM, Agrawal A (2016) Drug-induced bullous pemphigoid. J Gen Intern Med 31(11):1393\u20131394. https:\/\/doi.org\/10.1007\/s11606-016-3679-1","journal-title":"J Gen Intern Med"},{"key":"6169_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2004.06.051","volume":"54","author":"VQ Chung","year":"2006","unstructured":"Chung VQ, Moschella SL, Zembowicz A, Liu V (2006) Clinical and pathologic findings of paraneoplastic dermatoses. J Am Acad Dermatol 54:745","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"6169_CR13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jamadermatol.2013.4957","volume":"149","author":"LE Wiznia","year":"2013","unstructured":"Wiznia LE, Subtil A, Choi JN (2013) Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent. JAMA Dermatol 149(9):1071\u20131075","journal-title":"JAMA Dermatol"},{"issue":"9","key":"6169_CR14","first-page":"1052","volume":"12","author":"N Cleaver","year":"2013","unstructured":"Cleaver N, Ramirez J, Gildenberg S (2013) Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature. J Drugs Dermatol 12(9):1052\u20131055","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"6169_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/1203475417752369","volume":"22","author":"J Pinard","year":"2018","unstructured":"Pinard J, Patel M, Granter SR, Vleugels RA, Merola JF (2018) Subacute cutaneous lupus erythematosus induced by palbociclib. J Cutan Med Surg 22(3):341\u2013343","journal-title":"J Cutan Med Surg"},{"key":"6169_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14716","author":"JB Freedman","year":"2019","unstructured":"Freedman JB, Herskovitz I, Maderal AD (2019) Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.14716","journal-title":"Int J Dermatol"},{"key":"6169_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13696","author":"G Calabrese","year":"2020","unstructured":"Calabrese G, Licata G, Gambardella A, De Rosa A, Ronchi A, Argenziano G (2020) A case of discoid lupus erythematosus because of palbociclib. J Cutan Pathol. https:\/\/doi.org\/10.1111\/cup.13696","journal-title":"J Cutan Pathol"},{"issue":"10","key":"6169_CR18","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/archdermatol.2012.1856","volume":"148","author":"E Wilkerson","year":"2012","unstructured":"Wilkerson E, Hazey MA, Bahrami S, Callen JP (2012) Golimumab-Exacerbated Subacute Cutaneous Lupus Erythematosus. Arch Dermatol 148(10):1186\u20131190","journal-title":"Arch Dermatol"},{"issue":"2","key":"6169_CR19","first-page":"627","volume":"14","author":"F Furukawa","year":"1999","unstructured":"Furukawa F (1999) Antinuclear antibody-keratinocyte interactions in photosensitive cutaneous lupus erythematosus. Histol Histopathol 14(2):627\u2013633","journal-title":"Histol Histopathol"},{"issue":"5","key":"6169_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jdcr.2017.12.015","volume":"4","author":"T Karagounis","year":"2018","unstructured":"Karagounis T, Vallurupalli M, Nathan N et al (2018) Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep 4(5):452\u2013454","journal-title":"JAAD Case Rep"},{"issue":"7","key":"6169_CR21","doi-asserted-by":"publisher","first-page":"1325.e3","DOI":"10.1016\/j.ajem.2018.04.019","volume":"36","author":"S Widmer","year":"2018","unstructured":"Widmer S, Grossman M (2018) Chemotherapy patient with stevens-johnson syndrome presents to the emergency department: a case report. Am J Emerg Med 36(7):1325.e3-1325.e4","journal-title":"Am J Emerg Med"},{"key":"6169_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-3083.2010.03803.x","volume":"25","author":"S Santoro","year":"2011","unstructured":"Santoro S, Santini M, Pepe C, Tognetti E, Cortelazzi C, Ficarelli E, De Panfilis G (2011) Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 25:596\u2013598","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"6169_CR23","first-page":"797","volume":"35","author":"NI Abdou","year":"2008","unstructured":"Abdou NI, Rider V, Greenwell C, Li X, Kimler BF (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol. 35(5):797","journal-title":"J Rheumatol."}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06169-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06169-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06169-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T12:42:19Z","timestamp":1625575339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06169-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6169"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06169-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"15 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patients in this manuscript have given written informed consent to publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}